Role of Rosuvastatin in Treating Diabetes Mellitus, Heart Failure and Hyper Cholesterolemia

Journal of Research in Medical and Dental Science
eISSN No. 2347-2367 pISSN No. 2347-2545

All submissions of the EM system will be redirected to Online Manuscript Submission System. Authors are requested to submit articles directly to Online Manuscript Submission System of respective journal.

Research - (2022) Volume 10, Issue 7

Role of Rosuvastatin in Treating Diabetes Mellitus, Heart Failure and Hyper Cholesterolemia

Tanishq Kumar* and Benumadhab Ghosh

*Correspondence: Tanishq Kumar, Department of Pharmacology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed to be University), Sawangi (Meghe), Wardha, Maharashtra, India, Email:

Author info »


Rosuvastatin is another age HMG-CoA reductase inhibitor exhibiting interesting therapeutic and pharmacodynamics characteristics. It consists of a limited extra hepatic tissue perfusion, a low potential for CYP3A4 connections, and a significant LDL-C lowering limit, and hence has undeniable advantages. In this review article, we explore the pharmacological aspects of rosuvastatin, highlighting its reliability. We also examine the significant medical investigations involving hereditary hypercholesterolemia and its association to various statins. Ultimately, we will address its role in clinical treatment. Coronary illness (CHD) is the main source of death around the world. The viability and security of statins in essential and optional avoidance of CHD is affirmed in a few enormous investigations. The most notable statin to hit the market is rosuvastatin. It is observed that 5-20 mg/day is effective and safe in lowering LDL in different ages of individuals with hypercholesterolemia, even in the elderly. Rosuvastatin also has relaxing and anti-atherosclerotic properties, such as lowering arterial thickness and subsequently deteriorating plaque region. Several articles have determined approximately 92 percent of individuals having type 2 diabetes who do not have a heart disease are at risk of developing a dyslipidemic profile. According to current cardiovascular risk guidelines, people diagnosed with DM Type-II should be regarded under high risk of CVD and must get lipid lowering medication to reduce LDL to less than 2.5 millimol/L. Statins have revolutionized CVD management since their introduction. Rosuvastatin is the most recent statin to be introduced.


Rosuvastatin, Diabetes mellitus, Hyperlipidemia, Coronary illness, Statins


Ischemic coronary disease, the leading causes of death globally, rendering it a major medical challenge. As said by world Health Organisation (WHO) data, IHD is responsible for 12.8 percent of all fatalities, including strokes as well as various neurovascular illnesses contributing to the remaining 10.8 percent. UK’s statistics concluded by health surveys conducted in England show that although fatalities are decreasing, the severity of heart disease is increasing. Observational data has developed a comprehensive link involving cholesterol as well as the prevalence of heart disease. Low density lipoprotein cholesterol (LDL-C is favorably linked to incidence and death, whereas high density lipoprotein cholesterol (HDL-C) is negatively linked (HDL-C) [1,2].

Statins comprise of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors which lower total and LDL cholesterol [3]. The risk of cardiovascular episodes is reduced drastically, by LDL-C lowering statins which have been indicated conclusively by several large controlled studies [4].

Studies have indicated that using inhibitors of HMG CoA avoid premature onset as well as progression of cardiovascular incidents amongst populations suffering from IHD despite the circulating levels of cholesterol [5,6]. Aside from their advantageous cholesterol-reducing effects, statins have other physiological benefits. The most significant ones include: Statins strengthen utility of vascular cell walls, stabilize fat laden masses lodged in arteries and suppress pro-inflammatory action in vascular tubes [7]. Additionally, substantial assessments aftermarket launch have revealed that persistent statin consumption triggers no significant adverse effect [8].

Declining cardiovascular episodes due to statin consumption is indicative of decreasing concentrations of LDL-C. Rising necessity of strict targets for LDL-C minimization in heart disease risk projection has put emphasis on maximal intensity statin treatment [9]. LDL-C minimization is influenced by various statins exhibiting diversified influence, where Rosuvastatin is the most potent in contrast to fluvastatin which hardly contributes [10]. Statins differ amongst themselves in lipophilic and digestive properties. Such contrasting properties highly influence perfusion of tissues outside the liver as well as drug linkages with possible health benefits [11]. Rosuvastatin exhibits minimal infiltration of tissues outside liver, a limited propensity for CYP3A4 associations and a significant LDL-C reducing threshold, thus it is concluded to be beneficial. It has a possible role towards the direct and indirect treatment of heart disease amongst a variety of populations which include several heart related disorders in old aged people, kidney dysfunction, diabetes as well as combined application acting as an adjunct to various medications which reduce lipid content constituting topics of extensive clinical research.


Findings suggest that rosuvastatin decreases ischemic stroke although it has little to no advantages on transient ischemic episodes and hemorrhagic strokes. Such advantages are evident throughout all demographic groups, comprising of females, people who don’t smoke as well as generally healthy individuals. Each millimol/L drop in LDL-C resulted in a 39% decrease in the corresponding risk of stroke. Overall significant improvements appeared to be typically reserved for those who acquired LDL-C 1.8 mmol/L and hsCRP 2mg/L. Earlier researches utilizing various statins, often including WOSCOPS or MEGA has not established a substantial decrease in the prevalence of strokes [12,13].

Rosuvastatin doesn’t just diminish the severity of cerebrovascular accidents, which is shown in a study, yet in addition eases the pace of movement of atherosclerotic diseases seen in several researches [14]. Sufficient research has not yet been conducted on the effects of rosuvastatin for prevention of strokes in people who have had a stroke in the past. Studies have found that 80mg of Atorvastatin everyday brought about critical decrease in repetitive stroke [15]. An additional examination to a study discovered the impact seemed to be more noticeable among individuals with established carotid stenosis. Escalated treatment results in comparable advantages.

Relation with diabetes

Higher incidences of CAD are associated to type II Diabetes. According to a study, every 1 millimol/L rise in concentration of LDL-C has shown 57% higher chances of cardiac complications. Also, diabetic’s chances of stroke can be predetermined by their LDL-C levels [16]. A study claimed that Atorvastatin is believed to lower the chances of any cardiac complications and stroke in diabetic individuals with low levels of HDL-C [17].

Therefore, demanding the necessity of statin drugs involvement in order to attain precaution in diabetics. Simvastatin has been proven to lower chances of cardiac complications in such individuals (diagnosed with diabetes) having heart conditions. Out of the entire study group no single case had any prominent cardiac deaths due to small sample group [18].

A randomized twofold visually impaired twofold faker, multicenter, stage IIIb, equal gathering study to think about the adequacy and security of rosuvastatin (10 mg and 20 mg), and atorvastatin (10 mg and 20 mg) in patients with type 2 diabetes mellitus (ANDROMEDA) showed that rosuvastatin delivered more noteworthy decreases in LDL-C, ApoB and complete cholesterol when contrasted and equivalent dosages of atorvastatin. A more prominent extent regarding individuals under Rosuvastatin therapy accomplished euro LDL-C objectives contrasted with people under atorvastatin therapy [19]. Study showed that diabetic population suffering from borderline elevated levels of cholesterol under rosuvastatin delivered more noteworthy decreases in apoproteinB B: apoproteinA-oneconcentrations, LDL-C and absolute cholesterol [20]. Unrivaled impact by Rosuvastatin was different to Atorvastatin regarding decrease of cholesterol which was proved in a scientific experiment [21].

Two most highly regarded dangerous diseases of today i.e Diabetes and heart disorders are believed to be the leading cause of deaths with their treatment not curing the diseases permanently [22]. Gastrointestinal disturbances in metabolism of sugars and fats both being ATP rich compounds in Type 2 diabetes mellitus adds up to the acceleration of incidences plus progression in fat laden masses in blood vessels and prompting seriously unfavorable anticipation [23]. Up until this point, a few investigations have affirmed issues in breakdown of lipid in blood which implies this issue to be autonomous danger agent in the advent in previously discussed infections [24]; accordingly, being vital regarding management of lipid concentration in blood of people with type II diabetes and heart illness. The recommended drug of choice for control of breakdown of lipid concentration in blood in today’s medical scenario is Rosuvastatin which belongs to a family of statin, is essentially removed due to age progression in Aspergillus terreus, capable of adequately smother amalgamation regarding cholesterol present interiorly, along these lines bringing down the blood lipid level [25]. Thus, the job of this drug of choice regarding directing lipid concentration in blood is already been proved in a clinical set up. Further elucidation of the action of rosuvastatin, notwithstanding action upon blood vessel capacities including other issues in people suffering from Type II diabetes mellitus with heart disorders should be done. It proposed the fact of administration of rosuvastatin has the capacity of adequately directing lipid concentration in blood of people suffering from two diseases of type II diabetes and heart disorders. As far as testing records identified with Type II DM, the fact of dissimilarity and previously done mediation, along with degree of FINS post intercession has been found to be astoundingly much greater, in regard to HOMA-IR concentration post intercession had been discovered to be fundamentally miniscule. The observation was on application of rosuvastatin in individuals suffering from type II DM muddled in heart illness is critical worth furthering developed insulin work in its efficiency and enhancing insulin opposition. Regarding type II DM it proposed convolution with heart disorders, drug administration utilizing rosuvastatin surprisingly diminish provocative reactions and work on blood vessel wall capacities. Moreover, relationships of changes in TC with those in FINS, hs-CRP and ET-1 during time spent in treatment of people suffering from Type II DM and heart illness utilizing rosuvastatin were dissected leading to the discovery that concentrations of TC was contrarily corresponded with FINS level however decidedly associated with the degrees of hs-CRP and ET-1.

Role in heart complications

Cardiac failure exists as a typical clinical issue that affects people of industrialized and agricultural nations. There are numerous prescriptions with a positive heart withdrawal effect (favorable inotropics like glycosides, adrenoceptor stimulants and phosphodiesterase inhibitors, countless heart diluents(like(ACE) inhibitors) and a couple of other types of medications whose overall conclusion were under evaluation among the medications used to treat heart failure today. Statins include significant medications that are extensively endorsed for excess lipid levels as well as patients suffering from cardiac issues due to many various features, like lowering cholesterol, enhanced endothelial function, protection against oxidative stress, neovascularization as well as immunomodulatory workouts. The statin family of drugs all reduces LDL cholesterol levels. Overall, each effectively affects diminishing cholesterol and cardiovascular attacks [26]. Due to their kind of capacity, these medications play a fundamental restorative part in cardiovascular atherosclerotic patients and decrease the death pace of hypercholesterolemic infections by around 30% [27]. Statins induce the expression of the liver’s LDL receptors subsequently bringing down the concentration of cholesterol without the presence of blood. Statins lessen LDL cholesterol approximately by an average of 25-65% and the fatty acid content by 15-45%. They also boost HDL by 7 to 18% [28-30]. These treatments reduce the risk of coronary course infection and as a result, the total mortality rate of heart disease patients, owing to the adverse effects of clinical testing. Accessible insights in regards to all these studies demonstrate advantageous impact such as a 40-45 percent decrease in mortalities through cardiac supply route illnesses sicknesses in individuals with a concerning level of LDL [31].

Dangers in use of statin

In spite of the fact that statins, with their undeniable capacities, decreasingly affect LDL cholesterol and along these lines work on the overall state of patients with HF; in any case, as indicated by certain examinations, reduced cholesterol levels in people taking statins result in negative side effects for these patients [32,33]. As to gainful impacts, they are accounted for by a low level of serum cholesterol is related to a more awful anticipation towards heart failure as well as levels of ubiquinone seem essentially diminished post statin utilization [34]. Statins are significant medications that are comprehensively endorsed for hyperlipidemia and patients suffering heart diseases owing to various characteristics, like decrease in cholesterol, endothelial capacity strengthening, hostile to oxidative, mitigating, vascularization and modulation of immune exercises. Statin impacts incorporate restoring endothelial work, upgrading the steadiness of fat laden masses lodged in arteries, standardization of thoughtful outpouring, ant proliferative and anticipation of thrombocyte conglomeration are various different useful statin characteristics.

There seems to be proof that statins decrease cardiomyocytes Within apoptotic interaction, oxidation tension, irritation and the development of Neuro humoral stiffness in HF patients with myocardial hypertrophy. In any case, the way that these medications have no incidental effects has not been affirmed in all investigations, as statins forestall the creation of specific advantageous and defensive variables, like CoQ10, while hindering the creation of explicit proteins associated with pathologic instruments. As of late, it has been conjectured that, notwithstanding the beneficial outcomes announced, high portions of statins in patients with long haul heart failure lead to advance in cardiovascular breakdown by repressing CoQ10 blend and escalating hypertrophy. Thus, it very well may be expressed that the benefit of utilizing statins relies upon variables, for example, stroke part, and the presence of other standard signs, for example, atherosclerotic infections or high LDL-C.


Leading cause of mortality in world is coronary heart disease. The use and potency of the administration of statin in treatment of heart diseases has been proved in large research studies, Rosuvastatin being the most useful drug available. The population with their age past sixty has been prone to CHD and other heart disease related episodes eventually resulting in loss of life in these strata of population. Other secondary comorbidities which have become very common to people with sedentary lifestyle such as elevated lipid in bold, Type II Diabetes and nicotine consumption will only increase the risk and danger in this age group. Rosuvastatin is one of the statins that enjoys a few benefits in treating more established patients: For some individuals, low dosage works and for some large concentration is required for treatment. Also Rosuvastatin is very secure among geriatric population taking various drugs apart from statins as it is not utilized by CP450 compound therefore making the statin safe for use.

Older individuals (above the age of eighty) naturally, are subject to loss of physiological functionality of organs, particularly hepatic and urinary system capacity, numerous drugs, and lot of age related issues. Along these lines, the security of a medication is of extraordinary worry, similar to its adequacy. Nonetheless, old patients are not generally tried out enormous randomized clinical preliminaries. In the meantime, this group of old people is prone to very large number of heart related diseases ultimately leading to the use of statins for their treatment.

According to experimental study reports, research has been done under this regard in geriatric population. The research study was not of large magnitude but it actually concluded in giving some content and results that is of importance for the study on this age group. The outcomes of this research were that Rosuvastatin is very powerful and healthy for the geriatric population suffering from chronic elevated lipid levels or chronic heart diseases [35,36]. No adverse reactions were observed in this research study. Rosuvastatin is a forceful lipid-bringing down medicine; According to a study, Rosuvastatin has been claimed that the drug is successful regarding condition of carotid atherosclerosis having elevated lipid content or not among China’s population. Additionally, the benefits include mitigation and opposed action against atherosclerosis among different strata of people suffering from disease like with increased lipid levels, chronic heart related disorders and high blood pressure. There are no serious adverse effects of the drug even though when the concentration of the drug is more than twenty mg/day [37-40]. Rosuvastatin has as of now been generally assessed in a few enormous examinations around the world, and has set up a significant job amongst heart related problems. For patients the most easily available statin drug is Rosuvastatin which can be used for treatment.


Statins consist of important medications which are comprehensively endorsed to cardiovascular and hyperlipidemia because of the various properties, like cholesterol decrease, endothelial capacity improvement, hostile to oxidative, calming, and formation of blood vessels. Statin impacts incorporate work of betterment of endothelium tissues, upgrading strength of atherosclerotic plaques, standardization of thoughtful surge; inhibiting cell growth as well as counteraction by thrombocyte accumulation constitutes other practical functions of statins.

Proof exists which portrays that remedial job done by statins in heart failure, because of increase in ventricular myocardial mass may lead to a decrease of CMs misfortune in apoptotic interaction, oxidative pressure, irritation, which furthermore leads to the emergence of neurohormonal discrepancy. In any case, the way that these medications have no incidental effects has not been affirmed in all examinations, as statins forestall the creation of specific valuable and defensive components, like CoQ10, while repressing the creation of explicit proteins engaged with pathologic systems.

The impact of rosuvastatin other than on endothelium tissues capacities as well as hazardous reaction variables in people with diabetes mellitus type 2 and cardiac illness should be further elucidated. It proposed that the rosuvastatin therapy can adequately direct the blood cholesterol level in such above mentioned patients. These medications lessen the danger of coronary course infection and accordingly decrease the general death pace of heart patients. As of late, it has been conjectured that, notwithstanding the beneficial outcomes announced, statins in high portions of present in people who suffer from long haul heart failure may escalate to an advance in cardiovascular breakdown which is brought about by repressing Coenzyme Q10 blend which leads to escalation in hypertrophic action. Therefore, it can be assumed that the benefit of utilizing statins relies upon variables, for example, stroke part, as well as the presence of various common signs, for example, plaque buildup inside arteries or high amount of low density lipid cholesterol. Rosuvastatin has as of now been generally assessed in a few enormous examinations around the world, and has set up a significant job for cardiac illnesses. Rosuvastatin is known to be the most recent statin accessible to the public.

In view of its intensity, rosuvastatin can be utilized at extremely low portions. Various reports are arising about discontinuous or beat treatment which is better endured at this point keeps up with sensible lipid control. Smaller doses of rosuvastatin, like certain other strong statins, may be utilized in individuals from Asian countries in order to diminish hazard of destruction of striated muscle cells.

Finally, rosuvastatin seems to be a powerful and well-tolerated statin that is an effective 2nd therapy among most individuals who require essential or peripheral counteraction. Usually, with a background marked by past statin bigotry or numerous medication treatments, low portion rosuvastatin might be thought of. Rosuvastatin should be evaluated as a possible 1st medication for patient groups at exceptionally high risk who need a significant reduction in LDL-C. Its merits vs. expenditure in those with reduced cardiovascular risk are still being debated.


  1. Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. Br Med J 1991; 303:276-282.
  2. Indexed at, Google Scholar, Cross Ref

  3. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease: The Framingham Study. Am J Med 1977; 62:707-714.
  4. Indexed at, Google Scholar, Cross Ref

  5. Illingworth DR, Tobert JA. A review of clinical trials comparing HMG-CoA reductase inhibitors. Clin Ther 1994; 16:366-385.
  6. Indexed at, Google Scholar

  7. Heart Protection Study Collaborative Group. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: A randomised placebocontrolled trial. Lancet 2002; 360:7-22.
  8. Indexed at, Google Scholar, Cross Ref

  9. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): Multicentre randomized placebo-controlled trial. Lancet 2004; 364:685-696.
  10. Indexed at, Google Scholar, Cross Ref

  11. Koren MJ, Hunninghake DB, Alliance Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: The alliance study. J Am College Cardiol 2004; 44:1772-1779.
  12. Indexed at, Google Scholar, Cross Ref

  13. Durrington P. Hyperlipidaemia 3Ed: Diagnosis and management. CRC Press 2007.
  14. Indexed at, Google Scholar

  15. Alsheikh-Ali AA, Ambrose MS, Kuvin JT, et al. The safety of rosuvastatin as used in common clinical practice: A postmarketing analysis. Circulation 2005; 111:3051-3057.
  16. Indexed at, Google Scholar, Cross Ref

  17. Waters DD, Guyton JR, Herrington DM, et al. Treating to new targets (TNT) study: Does lowering low-density lipoprotein cholesterol levels below currently recommended guidelines yield incremental clinical benefit?. Am J Cardiol 2004; 93:154-158.
  18. Indexed at, Google Scholar, Cross Ref

  19. White CM. Pharmacokinetic implications of HMG CoA reductase inhibitors. Connecticut Med 2000; 64:533-535.
  20. Indexed at, Google Scholar

  21. White CM. A review of the pharmacologic and pharmacokinetic aspects of rosuvastatin. J Clin Pharmacol 2002; 42:963-970.
  22. Indexed at, Google Scholar, Cross Ref

  23. Shepherd J, West of Scotland Coronary Prevention Study Group. The west of Scotland coronary prevention study: A trial of cholesterol reduction in Scottish men. Am J Cardiol 1995; 76:113C-117C.
  24. Indexed at, Google Scholar, Cross Ref

  25. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): A prospective randomised controlled trial. Lancet 2006; 368:1155-1163.
  26. Indexed at, Google Scholar, Cross Ref

  27. Crouse JR, Raichlen JS, Riley WA, et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: The METEOR trial. JAMA 2007; 297:1344-1353.
  28. Indexed at, Google Scholar, Cross Ref

  29. Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. New Eng J Med 2006; 355:549-559.
  30. Indexed at, Google Scholar, Cross Ref

  31. Stevens RJ, Kothari V, Adler AI, et al. The UKPDS risk engine: A model for the risk of coronary heart disease in Type II diabetes (UKPDS 56). Clin Sci 2001; 101:671-679.
  32. Indexed at, Google Scholar, Cross Ref

  33. Pyörälä K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: A subgroup analysis of the scandinavian simvastatin survival study (4S). Diabetes Care 1997; 20:614-620.
  34. Indexed at, Google Scholar, Cross Ref

  35. Betteridge DJ, Gibson JM, Sager PT. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (<2 mg/L) and low-density lipoprotein cholesterol (<70 mg/dl) targets in patients with type 2 diabetes mellitus (from the ANDROMEDA study). Am J Cardiol 2007; 100:1245-1248.
  36. Indexed at, Google Scholar, Cross Ref

  37. Wolffenbuttel BH, Franken AA, Vincent HH, et al. Cholesterol‐lowering effects of rosuvastatin compared with atorvastatin in patients with type 2 diabetes–corall study. J Int Med 2005; 257:531-539.
  38. Indexed at, Google Scholar, Cross Ref

  39. Berne C, Siewert-Delle A. URANUS study investigators. Comparison of rosuvastatin and atorvastatin for lipid lowering in patients with type 2 diabetes mellitus: Results from the URANUS study. Cardiovasc Diabetol 2005; 4.
  40. Indexed at, Google Scholar, Cross Ref

  41. Faergeman O, Hill L, Windler E, et al. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with primary hypercholesterolemia. Cardiology 2008; 111:219-228.
  42. Indexed at, Google Scholar, Cross Ref

  43. Gungoren F, Besli F, Caliskan S, et al. Statin therapy may not effect NLR and MPV levels in patients with hypercholesterolemia: A retrospective study. Angiology 2016; 67:536-540.
  44. Indexed at, Google Scholar, Cross Ref

  45. Koshelskaya OA, Vinnitskaya IV, Konko TY, et al. Comparative randomized study of the effects of long-term therapy with rosuvastatin and with combination of atorvastatin and ezetimibe on carbohydrate metabolism and adipokynes levels in patients with coronary artery disease and diabetes mellitus. Kardiologiia 2015; 55:67-74.
  46. Indexed at, Google Scholar

  47. Terao Y, Satomi-Kobayashi S, Hirata KI, et al. Involvement of Rho-associated protein kinase (ROCK) and bone morphogenetic protein-binding endothelial cell precursor-derived regulator (BMPER) in high glucose-increased alkaline phosphatase expression and activity in human coronary artery smooth muscle cells. Cardiovas Diabetol 2015; 14:1.
  48. Indexed at, Google Scholar, Cross Ref

  49. Suthar KS, Vanikar AV, Trivedi HL. Acute kidney injury and quadriparesis due to rosuvastatin induced rhabdomyolysis-A case report. J Clin Diagn Res 2015; 9:OD08.
  50. Indexed at, Google Scholar, Cross Ref

  51. Jiang SY, Li H, Tang JJ, et al. Discovery of a potent HMG-CoA reductase degrader that eliminates statin-induced reductase accumulation and lowers cholesterol. Nature Commun 2018; 9:1-3.
  52. Indexed at, Google Scholar, Cross Ref

  53. Delahoy PJ, Magliano DJ, Webb K, et al. The relationship between reduction in low-density lipoprotein cholesterol by statins and reduction in risk of cardiovascular outcomes: An updated meta-analysis. Clin Therap 2009; 31:236-244.
  54. Indexed at, Google Scholar, Cross Ref

  55. Kazi DS, Penko JM, Bibbins-Domingo K. Statins for primary prevention of cardiovascular disease: review of evidence and recommendations for clinical practice. Med Clin 2017; 101:689-699.
  56. Indexed at, Google Scholar, Cross Ref

  57. Mahmoudvand H, Sepahvand A, Khatami M, et al. Prevalence and associated risk factors of Cystoisospora belli and Cyclospora cayetanensis infection among Iranian patients with colorectal cancer. J Parasitic Dis 2019; 43:402-405.
  58. Indexed at, Google Scholar, Cross Ref

  59. Odden MC, Pletcher MJ, Coxson PG, et al. Cost-effectiveness and population impact of statins for primary prevention in adults aged 75 years or older in the United States. Ann Int Med 2015; 162:533-541.
  60. Indexed at, Google Scholar, Cross Ref

  61. Logue J, AL-Ghibiwi H, Alamri AA, et al. Systematic review of studies exploring reasons for statin non-adherence and of randomized controlled trials of interventions to improve adherence. Atherosclerosis 2015; 241:e52.
  62. Google Scholar

  63. Krum H, McMurray JJ. Statins and chronic heart failure: Do we need a large-scale outcome trial?. J Am College Cardiol 2002; 39:1567-1573.
  64. Indexed at, Google Scholar, Cross Ref

  65. Böhm M, Hjalmarson A, Kjekshus J, et al. Heart failure and statins—why do we need a clinical trial?. Zeitschrift Für Kardiologie 2005; 94:223-230.
  66. Indexed at, Google Scholar, Cross Ref

  67. Tousoulis D, Charakida M, Stefanadi E, et al. Statins in heart failure. Beyond the lipid lowering effect. Int J Cardiol 2007; 115:144-150.
  68. Indexed at, Google Scholar, Cross Ref

  69. Schwartz GG, Bolognese MA, Tremblay BP, et al. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: A randomized, controlled trial. Am Heart J 2004; 148:105.
  70. Indexed at, Google Scholar, Cross Ref

  71. Athyros VG, Katsiki N, Tziomalos K, et al. Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: A post hoc analysis of the GREACE study. Arch Med Sci 2013; 9:418-426.
  72. Indexed at, Google Scholar, Cross Ref

  73. Xue-song QI. Efficacy and safety of different doses of rosuvastatin on carotid atherosclerosis patients complicated with hyperlipidemia: A comparative study. J Clin Med Practice 2012; 11:27-29.
  74. Google Scholar

  75. Andhale A, Acharya S, Pratapa SK, et al. An unusual case of acute heart failure in a body builder: Case Report. Med Sci 2020; 24:1744-1748.
  76. Google Scholar

  77. Chiwhane A, Burchundi S, Manakshe G, et al. Incremental prognostic value of anemia in acute coronary syndrome from a rural hospital in India. Global Heart 2020; 15.
  78. Indexed at, Google Scholar, Cross Ref

  79. Roe MT, Li QH, Bhatt DL, et al. Risk categorization using new American College of Cardiology/American Heart Association guidelines for cholesterol management and its relation to alirocumab treatment following acute coronary syndromes. Circulation 2019; 140:1578-1589.
  80. Indexed at, Google Scholar, Cross Ref

Author Info

Tanishq Kumar* and Benumadhab Ghosh

Department of Pharmacology, Jawaharlal Nehru Medical College, Datta Meghe Institute of Medical Sciences (Deemed to be University), Sawangi (Meghe), Wardha, Maharashtra, India

Received: 08-Jun-2022, Manuscript No. JRMDS-22-66205; , Pre QC No. JRMDS-22-66205 (PQ); Editor assigned: 10-Jun-2022, Pre QC No. JRMDS-22-66205 (PQ); Reviewed: 24-Jun-2022, QC No. JRMDS-22-66205; Revised: 29-Jun-2022, Manuscript No. JRMDS-22-66205 (R); Published: 06-Jul-2022